BioPharmSignal logoBioPharmSignal

Biotech News

Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy

Lexicon Pharmaceuticals (LXRX)Lexicon PharmaceuticalsClinical readout

-- Patient demographics consistent with prior studies of other agents in HCM and reflect real-world clinical practice --

-- Mean baseline KCCQ-CSS of 59 shows considerable symptom burden at study entry –

Related news

LXRXLexicon Pharmaceuticals2026-07-27 12:30 EST

Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)

LXRXLexicon Pharmaceuticals2026-08-24 12:30 EST

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

MISTMilestone Pharmaceuticals Inc.2026-09-24 12:00 EST

Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR

MISTMilestone Pharmaceuticals Inc.2026-08-21 12:00 EST

Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)

SGMTSagimet Biosciences2026-10-22 11:00 EST

Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne

RYTMRhythm Pharmaceuticals2026-08-04 10:55 EST

Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity

SGMTSagimet Biosciences2026-08-25 11:00 EST

Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026

RYTMRhythm Pharmaceuticals2026-07-08 21:07 EST

Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity

VKTXViking Therapeutics2026-10-14 11:05 EST

Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity

ALGSAligos Therapeutics2026-07-13 12:00 EST

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection

View all latest news

Lexicon Pharmaceuticals

Genetically Informed Drug Discovery Lexicon Pharmaceuticals uses human-genetic insights to discover and develop medicines for cardiometabolic and neurologic diseases. Sotagliflozin Franchise Sotagliflozin is a dual SGLT1 and SGLT2 inhibitor. It is marketed as INPEFA for heart-failure-related indications, while the ZYNQUISTA application...

Recent company news

LXRXLexicon Pharmaceuticals2026-10-29 12:30 EST

Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026

LXRXLexicon Pharmaceuticals2026-10-23 12:30 EST

Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy

LXRXLexicon Pharmaceuticals2026-10-21 12:30 EST

Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease

LXRXLexicon Pharmaceuticals2026-09-01 20:05 EST

Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences

LXRXLexicon Pharmaceuticals2026-08-31 12:30 EST

Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure

Stock data

Close
1.61 USD
Market cap
839.53M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States